Blackstone Inc., alongside several affiliated entities, reported to regulators the sale of a sizable quantity of Medline Inc.'s (NASDAQ:MDLN) Class A Common Stock. Furthermore, Stephen A. Schwarzman, the founder, was also listed as participating in these transactions.
The filings detailing these sales were submitted on May 28, 2026. Specifically, the reporting parties disposed of a total of 33,317,824 shares, generating an aggregate value of roughly $1.22 billion for the transaction.
Details of the Stock Disposition
On May 28, 2026, the sales were executed at a price point of $36.5375 per share. This specific selling price was derived from the public offering price of $37.00 per share, after accounting for underwriting discounts and commissions totaling $0.4625 per share, as detailed in the accompanying footnotes to the filing.
Despite this significant institutional sale, Medline's stock is currently observed trading at $35.77. This price point places the stock close to its 52-week low of $34.89, suggesting a period of market challenge for the healthcare equipment supplier.
Key Reporting Entities and Ownership Structure
The group of reporting entities involved in these transactions is extensive, including BCP 8 Holdings Mozart Manager L.L.C., BMA VIII L.L.C., Blackstone Holdings II L.P., Blackstone Holdings I/II GP L.L.C., Blackstone Inc., Blackstone Group Management L.L.C., and Stephen A. Schwarzman. It is noted that all these entities are listed as holding ten percent ownership stakes in Medline Inc.
The filing further clarified the relationship between key figures, indicating that Stephen A. Schwarzman controls Blackstone Group Management L.L.C. This group, in turn, holds a controlling interest in both Blackstone Inc. and its various associated holding entities.
Additional Transactions on May 28th
In addition to the reported sales, another affiliated entity, Mozart Aggregator II LP, conducted an in-kind distribution of shares. On the same date, May 28, 2026, this specific entity distributed 438,214 shares of Class A Common Stock to one of its investors and other affiliated entities.
It is important to distinguish that this was an in-kind distribution rather than a direct sale transaction, and consequently, no price per share was reported for this particular transfer. Following the completion of these transactions, the reporting parties collectively maintain a substantial indirect holding of Medline Inc. shares. Each individual reporting person explicitly stated that they disclaim beneficial ownership of securities held by other reporting persons, except to the limited extent of their own pecuniary interest.
Recent Corporate Developments and Market Signals
More recent corporate news provides additional context regarding Medline's operational status and market reception. Recently, Medline Inc. announced the successful completion of a secondary offering. Through this process, 72.6 million shares of Class A common stock were offered at $37 per share.
This secondary offering was managed by several affiliated stockholders: Blackstone Inc., Hellman & Friedman LLC, and a subsidiary belonging to the Abu Dhabi Investment Authority. The fact that this offering was notably oversubscribed serves as an indicator of strong market demand for Medline's shares.
On the operational front, expansion efforts are also evident. Medline’s Canadian division secured its inaugural Prime Vendor agreement with Mohawk Medbuy. This marks a significant step in expanding the company's footprint outside the United States. Under this new arrangement, Medline Canada will be responsible for managing warehouse and supply chain logistics for hospitals located in Southwestern Ontario.
Market analysts have also weighed in on these developments. Specifically, Barclays recently adjusted its price target for Medline. The firm lowered its previous estimate from $50 to $45, while nonetheless maintaining an Overweight rating. This adjustment was attributed by the bank to ongoing concerns regarding material input costs, with fuel being highlighted as a particular area of concern.
These varied reports illustrate both the major institutional capital movements and the underlying commercial activities that define Medline’s current business profile and market perception.